• 1.

    Torres VE, et al.. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med 2017; 377:193042.

  • 2.

    Torres VE, et al.. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367:240718.

  • 3.

    Erickson KF, Chertow GM, Golhaber-fiebert JD. Cost effectiveness of tolvaptan in autosomal polycystic kidney disease. Ann Intern Med 2013; 159:382389.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness—The curious resilience of the $50,000-per-QALY threshold. N Engl J Med 2014; 371:796797.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Gansevoort RT, et al.. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: A position statement on behalf of the ERA-EDTA working groups on inherited kidney disorders and European renal best practice. Neph Dial Transpl 2016; 31:337348.

    • Crossref
    • Search Google Scholar
    • Export Citation

FDA Approval of Tolvaptan for PKD: Breakthrough Therapy vs. Value-Based Care

  • 1 Richard Lafayette, MD, is Editor-in-Chief of Kidney News. He is an investigator in the Otsuka PKD program and has received consulting fees in the past year.
Restricted access
Save